Articles tagged with Pancreatic Tumors
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers at the University of Wisconsin-Madison have developed a novel approach to treating pancreatic cancer using nano-drugs delivered via bacteria. The treatment bypasses the dense collagen barrier surrounding tumors, allowing for more effective delivery of immunotherapies.
Researchers discovered that the anatomical location of pancreatic tumors impacts treatment outcomes, suggesting a tumor-location-based model for improving patient care. The findings may lead to more specific treatment plans and better immunotherapy effectiveness.
The newly updated guidelines provide clinicians with the latest recommendations for staging and management of neuroendocrine tumors. The guidelines highlight recent changes for treating these tumors, including emerging molecular imaging techniques known as theranostics.
A new case report uses longitudinal multi-omics monitoring to detect a precancerous pancreatic tumor in a patient. The study highlights the potential of blood-based LMOM for early detection and personalized medicine, warranting further translational research.
Researchers discovered that liver cells secrete SAA proteins, which hinder T cell infiltration and attack tumors. Deleting SAA proteins increased survival times and likelihood of cures in mice with pancreatic tumors.
A pilot study by UCLA Health investigators suggests that treating patients with immunotherapy and chemotherapy before surgery may improve long-term outcomes for those with borderline resectable pancreatic cancer. The study found a higher rate of successful tumor removal and increased overall survival when compared to historical controls.
Researchers describe a new technique for minimally invasive removal of benign pancreatic tumors, preserving organ functionality and reducing complications. The retro-laparoscopic approach allows safe and effective tumor removal without removing healthy pancreatic tissue.
A recent study at Salk Institute evaluates the reliability of patient-derived organoids as a clinical model for pancreatic cancer. The findings reveal that organoids' gene expression and drug responses are not affected by commercial extracellular matrix brands, but one product increases growth rate.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
A new off-the-shelf vaccine has shown promise in treating pancreatic and colorectal cancers in patients with KRAS mutations. The study found that the vaccine significantly decreased tumor biomarkers and produced strong T-cell responses, leading to a reduced risk of relapse and death.
New research led by Johns Hopkins Medicine reveals that age-related changes in fibroblast cells enable pancreatic cancer tumor growth. The study found that older patients have poorer prognoses due to altered proteins released by fibroblasts, which promote cancer cell growth and spread.
A study published in Oncotarget has identified specific mutational and therapeutic landscapes of pancreatic cancer in the Russian population. By applying machine learning models to full exome individual data, researchers received personalized recommendations for targeted treatment options for each clinical case.
Researchers found that pancreatic cancer cells employ a 'favorable genetic reshuffling' to evade treatments, leading to a potential breakthrough in developing targeted drugs. Alternative splicing plays a crucial role in this process, and the study identifies a specific splicing regulator called 'Quaking' that promotes chemoresistance.
Researchers at Salk Institute discovered how anti-cancer drugs can prevent fibroblast activation, a protective barrier around pancreatic tumors. The therapy reduces tumor growth and slows disease progression in mice and human patients, offering a promising treatment for pancreatic cancer.
Researchers found that secreted frizzled-related protein 2 (SFRP2) is abundantly expressed in pancreatic cancer, with higher levels linked to poorer outcomes. Blocking SFRP2 may affect tumor growth, angiogenesis, and the immune system, making it a potential therapeutic target.
Scientists at Nagoya University have discovered a reliable cancer marker, stromal cell-derived factor 4 (SDF-4), that detects gastric cancer with high accuracy. The protein is found in high levels even in patients with stage I gastric cancer, suggesting its potential for early detection.
Scientists from Tokyo Medical and Dental University created a synthetic polymer biomaterial that mimics the pancreatic adenocarcinoma microenvironment, enabling them to identify potential therapeutic targets. The study successfully recapitulates the complex interactions between cancer stem cells and their niche.
Researchers found amoeboid cells in pancreatic cancer produce CD73, which drives spread and weakens immune system. Blocking CD73 reduced cancer spread to liver and decreased immune cell support.
A University of Massachusetts Amherst team demonstrates a protein antigen from a childhood vaccine can be delivered into malignant tumor cells to refocus the immune system against cancer. The bacteria-based intracellular delivering system shows promise in treating pancreatic, liver, and metastatic breast tumors.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
Researchers analyze neuroendocrine tumors at single cell resolution, unlocking key insights into tumor biology and potential evolution of tumor characteristics. The study reveals heterogeneity within tumor subtypes and identifies potential targets for immunotherapy treatment.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The study found that activating a super-enhancer leads to an increase in protein production, enabling rapid cell growth.
The CABINET trial showed statistically significant and clinically meaningful improvements in progression-free survival for patients with pancreatic and extra-pancreatic neuroendocrine tumors. The study also demonstrated a consistent safety profile for cabozantinib, with no new safety signals identified.
Researchers at Sylvester Comprehensive Cancer Center will investigate signaling mechanisms between myeloid-derived suppressor cells and pro-inflammatory cancer-associated fibroblasts in pancreatic cancer. The goal is to develop a nanoengineered immunotherapy that selectively disrupts these interactions to target treatment resistance.
Researchers create accurate tumor models using 3D bioprinting and a bioink made from Laponite, improving bonding and cross-linking capabilities. The study shows that Laponite enhances biological signaling in the tumor microenvironment, increasing cell viability and promoting anti-tumor drug development.
Researchers have found a key role for NFIC in acinar cell maturation and limiting tumour formation in the pancreas. The molecule helps acinar cells work properly, reducing the risk of pancreatic cancer.
A new combination treatment of GVAX vaccine, nivolumab, and urelemab has shown to increase the amount of cancer-killing immune cells in tumors and appear effective when given two weeks prior to surgery. The study found a median disease-free survival of 33.51 months and a median overall survival of 35.5 months.
Researchers discovered that Nerofe and Doxorubicin can downregulate KRAS signaling, leading to enhanced apoptosis in colorectal cancer cells. The combination also activates the immune system against tumor cells, increasing immunostimulatory cytokines and recruiting NK cells and M1 macrophages.
A Mayo Clinic study reveals that minimally invasive surgical procedure staging laparoscopy can identify cancer spread early and determine the stage of pancreatic cancer. The research found a higher risk of cancer spread in patients with certain factors, such as age and tumor markers.
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
Researchers have developed a sonodynamic cancer immunotherapy based on semiconducting polymer nanoparticles that can be activated by ultrasound, effectively treating orthotopic pancreatic cancer in mouse models. The treatment induces immunogenic cell death and kills cancer cells without causing excessive immune responses.
A keto diet may help reduce body weight and slow tumor growth in cancer patients. However, research found that this diet can cause early-onset cachexia, a lethal wasting disease, in mice with pancreatic and colorectal cancer. Pairing keto with corticosteroids prevented cachexia in mice, allowing them to live longer.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
UMC Utrecht researchers are conducting two new projects to treat cancer using image-guided interventions. One project uses MRI-guided radiotherapy for locally advanced pancreatic cancer, while the other employs ultrasound techniques for head and neck cancers.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
SpaceMarkers, a new machine learning software, can identify molecular interactions among distinct cell types in and around tumors. By analyzing spatial transcriptomics data, it reveals genes overexpressed due to cell-to-cell interactions, providing new avenues for understanding cancer progression and treatment responses.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.
The study revealed lower age-standardized rate of NENs incidence in China (1.14 per 100,000) compared to the USA (6.26 per 100,000). The most common sites for primary NEN tumors progressed were found to be the pancreas, stomach, lungs, and rectum.
Researchers identify SRSF1 as a key player in promoting pancreatitis and pancreatic cancer growth. High levels of SRSF1 are associated with worse patient outcomes, highlighting its potential as a target for new therapies.
A novel cell signaling pathway has been identified that could be targeted to treat aggressive pancreatic cancers. The High Mobility Group A1 (HMGA1) protein functions as a 'molecular switch' that activates genes required for tumor growth and invasion. Silencing HMGA1 or disrupting FGF19 signals in mouse models resulted in decreased tum...
Jeong Min Lee, KSR President and professor at Seoul National University Hospital, is honored with ARRS membership. He has published over 470 scientific articles and serves on the editorial board of several publications.
Researchers have developed an implantable nanofluidic device that delivers CD40 monoclonal antibodies to shrink pancreatic tumors, reducing treatment dosage by fourfold. The device's long-term controlled release avoids systemic side effects, offering a promising alternative for cancer patients.
A study published in the journal Cancer found that long-term pancreatic cancer survivors have a robust immune response and enriched gut microbiome species, including Faecalibacterium prausnitzii. The research suggests that these bacterial species may promote immune response to pancreas cancer.
A new radiotracer successfully detected 100% of primary tumors across multiple cancer types, outperforming the current standard. It also showed promise in detecting lymph node and distant metastases, offering a promising alternative for diagnosis and treatment.
Researchers at Karolinska Institutet discovered an immune cell in women with pancreatic cancer that blocks the immune response, leading to poor survival. The study identifies a specific protein FPR2 as a potential therapeutic target for immunotherapy in women.
Researchers at Garvan Institute of Medical Research found that introducing bacteria to a tumor's microenvironment triggers an immune response, activating neutrophils to destroy tumors in animal models. This breakthrough therapy targets neutrophils to improve cancer treatment outcomes.
The use of AI is improving diagnostic accuracy for digestive cancers, but challenges in data sharing and standardization hinder its widespread application. Researchers surveyed recent applications of AI to these deadly cancers, finding that AI can automate complex processes and detect patterns not visible to humans.
Researchers at VCU Massey Cancer Center found that simultaneous activation of Prdm16 and Smad4 proteins slows down pancreatic cancer progression. The study suggests a novel therapeutic approach to tackle this deadly disease.
Researchers explore CEACAM1, CEACAM5, and CEACAM6's pathological significance in cancer biology and immunology. The review highlights their interactions with pathogens and potential avenues for cancer therapy.
A recent study confirms that pancreatic cancer rates are rising faster in women than men, particularly among younger women and Black women. The rate of pancreatic cancer among women under the age of 55 increased by 2.4% compared to men of the same age, highlighting a significant disparity in mortality rates between the sexes.
Researchers found that primary cancer tumors have a sluggish conversion of nutrients to usable cellular energy, conserving energy for growth and metastasis. The discovery has vast implications for anti-cancer strategies, directing attention to slow energy metabolism.
Scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer to checkpoint blockade immunotherapy. A new drug combination, PD1-IL2v and anti-PD-L1, enhances anti-tumor immunity by stimulating specific T cells and reprogramming macrophages, leading to increased survival rates in tumor-bearing mice.
Researchers are working to understand the events contributing to pancreatic cancer development by studying gene abnormalities and their effects on the disease. Dr. Krushna Patra's lab is focused on understanding how genetic mutations like GNAS contribute to pancreatic cancer growth.
Researchers identified key metabolic pathways in tumor-associated macrophages that contribute to cancer development and progression. Targeting these pathways may provide a new perspective for immunotherapy-based cancer treatments.
Researchers from Johns Hopkins Medicine have identified a novel mechanism of tumor formation in kidney cancers, highlighting the role of overactive mTORC1 signaling pathway and loss of the TSC tumor suppressor gene. Activation of microphthalmia transcription factors (MITF) family by unopposed mTOR signaling may lead to abnormal cell gr...
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
Scientists at UCSF have engineered T cells to produce a potent anti-cancer cytokine that only activates in tumor cells, eliminating melanoma and pancreatic cancer in mice. The treatment uses IL-2, which supercharges T cells to kill cancer cells while protecting against infection, offering a promising new strategy for fighting hard-to-t...